Evidence map›Paper›PMID 41647727›Full record

ReviewESMO gastrointestinal oncology2023

Oligometastatic disease in esophagogastric cancer: an update of recommendations on definition, diagnosis, and treatment.

T E Kroese, S F C Bronzwaer, R van Hillegersberg, P S N van Rossum, H W M van Laarhoven

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO gastrointestinal oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

T E KroeseDepartment of Radiation Oncology, University Hospital Zurich, Zurich University, Zurich, Switzerland.
S F C BronzwaerDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht.
R van HillegersbergDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht.
P S N van RossumDepartment of Radiation Oncology, Amsterdam UMC, Location VUmc, Amsterdam.
H W M van LaarhovenDepartment of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligometastatic cancer is characterized by the presence of a restricted number of metastatic lesions extending beyond the primary tumor. Until recently, there was a significant lack of agreement concerning the precise definition and optimal treatment strategies for oligometastatic cancer in the context of esophageal or gastric malignancies. Here we provide an overview of the OligoMetastatic Esophagogastric Cancer (OMEC) project which was initiated to develop a multidisciplinary European consensus statement for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer. Additionally, we provide an updated systematic review of published and ongoing clinical studies on local metastasis-directed treatment of oligometastatic esophagogastric cancer.

Indexed as

Delphi consensusesophageal cancergastric cancermetastasectomyoligometastasisstereotactic body radiotherapy

Identifiers

PMID41647727
PMCPMC12836560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.